NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance
- PMID: 36927861
- DOI: 10.1183/13993003.02467-2022
NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance
Conflict of interest statement
Conflict of interest: In the past 36 months, D.W. Cockcroft has received research grants from the University of Saskatchewan, AstraZeneca Canada and Biohaven Pharmaceuticals, all unrelated to the current paper.
Comment on
-
Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.Eur Respir J. 2023 Mar 16;61(3):2201335. doi: 10.1183/13993003.01335-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36549708 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources